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Background: Host-species specificity of the human immunodeficiency virus (HIV) limits pathobiologic, diagnostic and
therapeutic research investigations to humans and non-human primates. The emergence of humanized mice as a model
for viral infection of the nervous system has overcome such restrictions enabling research for HIV-associated end organ
disease including behavioral, cognitive and neuropathologic deficits reflective of neuroAIDS. Chronic HIV-1 infection of
NOD/scid-IL-2Rgc
null mice transplanted with human CD34+ hematopoietic stem cells (CD34-NSG) leads to persistent
viremia, profound CD4+ T lymphocyte loss and infection of human monocyte-macrophages in the meninges and
perivascular spaces. Murine cells are not infected with virus.
Methods: Changes in mouse behavior were measured, starting at 8 weeks after viral infection. These were recorded
coordinate with magnetic resonance spectroscopy metabolites including N-acetylaspartate (NAA), creatine and choline.
Diffusion tensor magnetic resonance imaging (DTI) was recorded against multispectral immunohistochemical staining
for neuronal markers that included microtubule associated protein-2 (MAP2), neurofilament (NF) and synaptophysin
(SYN); for astrocyte glial fibrillary acidic protein (GFAP); and for microglial ionized calcium binding adaptor molecule 1
(Iba-1). Oligodendrocyte numbers and integrity were measured for myelin associated glycoprotein (MAG) and myelin
oligodendrocyte glycoprotein (MOG) antigens.
Results: Behavioral abnormalities were readily observed in HIV-1 infected mice. Longitudinal open field activity tests
demonstrated lack of habituation indicating potential for memory loss and persistent anxiety in HIV-1 infected mice
compared to uninfected controls. End-point NAA and creatine in the cerebral cortex increased with decreased MAG.
NAA and glutamate decreased with decreased SYN and MAG. Robust inflammation reflected GFAP and Iba-1 staining
intensities. DTI metrics were coordinate with deregulation of NF, Iba-1, MOG and MAG levels in the whisker barrel and
MAP2, NF, MAG, MOG and SYN in the corpus callosum.
Conclusions: The findings are consistent with some of the clinical, biochemical and pathobiologic features of human
HIV-1 nervous system infections. This model will prove useful towards investigating the mechanisms of HIV-1 induced
neuropathology and in developing novel biomarkers and therapeutic strategies for disease.
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Persistent HIV-1 infection commonly leads to cognitive,
behavioral and motor abnormalities called HIV-associated
neurocognitive disorders (HAND) [1-3]. Despite intensive
research, investigations seeking virus-associated central
nervous system (CNS) biomarkers and HAND therapies
have failed, in measure, due to the multifactorial nature of
disease and by few relevant small animal models [4-6].
The obstacles in generating a small animal model require
that viral tropism, neuroimmune activation, cognitive im-
pairments and CD4+ T cell losses are operative [1,7,8].
This has remained an unmet goal. Added to these obsta-
cles in mirroring human disease are the concomitant use
of abuse drugs, common opportunistic infections, hepatic
dysfunction, nutritional deficiencies, social demographics,
ongoing antiretroviral therapies, psychiatric illness, aging
and altered immune responses often seen in infected
humans [9]. The shift in human disease severity, from
overt dementia to subtle cognitive dysfunction, affects
changes disease demographics and as such has also made
modeling of human disease even more complex [10,11].
This has occurred as a consequence of the wide spread
use of antiretroviral therapy (ART) [3,12].
Despite considerable improvements in disease severity
up to half of infected patients show deficits in memory
and psychomotor functions. Disease can readily be seen
through neuropsychological testing using common met-
rics of cognitive function [13-16]. Such deficits are im-
portant as they can deeply affect the quality of life and
making research into ways to find better diagnostics and
therapeutic interventions timely and important [17-19].
However, in order to accomplish these goals model sys-
tems of current human disease are needed. Divergent
viral-induced immune and cognitive deficits seen as a
consequence of viral infection and ART need be consid-
ered. Indeed, early evidence that the terminal stages of
end organ HIV disease could be reflected in rodent
models of neuroAIDS was realized, over the past decade,
within our own laboratories [5,20-23]. However, despite
creating such models, no cross validation of the intersec-
tion between immune and behavior abnormalities were
realized. If this were possible, such a model could speed
the discovery of new pathways of disease towards better
understanding viral pathogenesis and even allow early
diagnostic studies [5,24,25]. To these ends, we now dem-
onstrate, for the first time, cross species transference of
immune and viral factors that lead to neurocognitive
deficits, neuropathology, brain metabolite alterations,
and brain subregion damage in virus-infected NOD/scid-
IL-2Rgc
null humanized mice (CD34-NSG). As such the
work represents a substantive step forward from current
models [22]. Remarkably, the observed metabolic [proton
magnetic resonance spectroscopy (1H MRS)], microstruc-
tural [diffusion tensor magnetic resonance imaging (DTI)],histologic and behavioral aberrations that characterize hu-
man disease are partially replicated in the mice and as
such mirror components of neuroAIDS. The model none-
theless provides unique insights in the biomolecular mech-
anisms of how HIV-1 infection affects neural function.
Results
Overview
Humanized mice for studies were divided into replicate
HIV-1 infected and uninfected animal groups. Imaging
was performed and blood samples acquired from all ani-
mals prior to and from four weeks to 16 weeks after in-
fection. At 16 week animals were perfused with normal
saline and the brains were harvested for histopatho-
logical evaluations. The experimental scheme is outlined
in Figure 1. The overall experimental design enabled
cross validation of all bioimaging, viral and, immune
tests with brain histopathology for each animal. In paral-
lel experiments, mice were evaluated for behavior by
open field activity (OFA). These were chosen to reflect
memory and anxiety in mice. Using replicate animals for
behavioral tests avoided confounding influences of the
anesthesia which was required for all bioimaging tests.
Immunologic and virologic features of HIV-1 infection in
humanized mice
CD34-NSG mice were monitored prospectively for blood
CD4+ and CD8+ T cells (Figure 2A). At 22 weeks of age,
mice (n = 20) were infected with HIV-1ADA. VL and CD4+
and CD8+ T cells were analyzed at 4, 8, 12 and 16 weeks
after infection (Figure 2B) from the 100 μl of blood col-
lected immediately following MRS and DTI studies. Steady
decreases in total CD4+ T cells with concomitant increases
in CD8+ cells were observed (Figure 2A) during the course
of HIV infection. Viral load (VL, copies/ml blood) peaked
at eight weeks after viral infection and all infected animals
had sustained VL (7.05 × 105 to 1.5 × 107) until 16 weeks
where reductions in total human cells (as measured by
CD45) mirrored decreases in VL (4.77 × 103 to 5.1 × 106).
Replicate uninfected controls (n = 10) demonstrated stable
CD45 and CD4/CD8 ratios throughout the study.
VL and identifications of infected cells
To assess the total number of human cells and VL in
the brain (copies/cc tissue), we dissected the cortex, ex-
tracted RNA, and real time RT-PCR performed for hu-
man CD45 and HIV-1gag. Comparison of VL in brains
(Figure 2C) with their peripheral blood VL at 16 weeks
(Figure 2D) showed that 3 animals with low peripheral
VL have significant levels of HIV-1gag in brain, indicat-
ing that peripheral viral loads are not correlated to brain
levels (r = 0.40, p = 0.264, Spearman correlation). The
data is expressed as total HIV-1 RNA copies/μg total
RNA after normalization with GAPDH. We identified
Figure 1 Timings for data acquisition in combined blood, neuroimaging, and histology assessments.
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and nervous system (brain). In regards to the former,
HIV-1 infected CD4+ T lymphocytes and monocyte-
macrophages were readily seen in both the follicular and
parafollicular areas, respectively (see Additional file 1A for
high power illustration). In contrast, only few numbers of
infected macrophages were observed in the brain as dual
labeled CD163 and HIV-1p24 cells. These were identified
in the meninges and perivascular spaces, as was reported
previously [5,21] (Additional file 1B and C). This served toFigure 2 VL and immune profiles in HIV-1 infected humanized mice.
HIV-1 infected mice (n = 10). The x-axis is the weeks following HIV-1 infecti
A. Mice were bled once every 4 weeks starting from 2nd week post-infectio
levels in the cortex was analyzed by real time RT-PCR. Data is expressed as
as an internal control). (D) For comparison, HIV-1 viral RNA in the peripherahighlight the lack of association between viral levels and
neuropathology and differences in numbers of infected
cells seen in the periphery (spleen) as compared to the
brain. Indeed, large numbers of infected CD4+ T lympho-
cytes and monocyte-macrophages were identified in the
spleen.
Behavioral deficits
The behavioral phenotypes of the HIV-1 infected human-
ized CD34-NSG mice were compared to uninfected(A) Flow cytometric analysis of CD4+ and CD8+ T cells in blood of
on. (B) VL dynamics in plasma of replicate blood samples from
n. Mean ± SEM are shown in both A and B. (C) Total HIV-1gag RNA
HIV-1 RNA copies/μg total RNA after normalizing against GAPDH (used
l blood at the end point is presented as viral RNA copies/ml.
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mice are placed in an enclosure that permits exploration of
a new environment. Spatial distribution, horizontal and ver-
tical movements are then measured to assess exploratory
behaviors. By the third trial, reductions in total horizontal
distance and vertical movements in uninfected controls
reflected mouse habituation associated with loss of anxietyFigure 3 Effect of HIV-1 infection of humanized CD34-NSG mice on co
experimental plan used and results. Three consecutive trials of OFA testing
were injected with PBS for OFA testing at the same time intervals. Mice we
Mice were bled from sub-mandibular vein under isoflurane inhalation anesthe
measured in the floor plane and vertical entries were measured in the vertical
in a new environment. Both measurements were reduced by the 2nd and 3rd
exhibit continued anxiety. *, p < 0.05 compared to 1st trial and #, p < 0.05 com
longitudinally before infection and 4 and 8 weeks after HIV-1 infection (n = 8
tested for OFA using 20 min session for three consecutive days (3 trials). Time
was automatically measured. The ratios were analyzed to assess anxiety behav
showed memory of the environment and reduced anxiety by spending more
* = p < 0.05 compared to trial 1 of pre-infection OFA, and # = p < 0.05 compar
Values are mean ± SEM. (B, bottom right) First five minute travel paths with d
trial 3 of an 8 week time point are shown.and memory of the environment [27,29]. Unlike uninfected
controls, HIV-1 infected animals showed unremitting ac-
tivity even at the third trial demonstrating continued anx-
iety (Figure 3A). Implementing OFA measurements over
successive trials at monthly intervals permitted inves-
tigation of the level of memory with HIV-1 infection
(Figure 3B). Analysis of central zone activities, expressed asgnition. (A) Schematic diagram is illustrated showing the
were done at 12–13 weeks after HIV-1 infection. Replicate control mice
re tested using 20 min sessions for three consecutive days (3 trials).
sia for flow cytometry and VL measurements. Total distance travelled
plane. These reflect the exploratory and habituation behavior of the mice
trials in uninfected controls reflecting habituation. HIV-1 infected animals
pared to 2nd trial. Values are mean ± SEM. (B) OFA testing was performed
for both control and infected animals). At each time point mice were
spent and distance traveled in the center compared to the periphery
ior and long term memory of environment. By 8 weeks, control mice
time in the central bright zone compared to HIV-1 infected mice.
ed to the corresponding trial performed at the same time from controls.
istance travelled for representative control and HIV-1 infected mice from
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(Figure 3B) indicated significant differences between animal
groups at 4 and 8 weeks after repeated testing and infec-
tion. Control animals demonstrated memory of the envir-
onment that is not seen in the infected animal groups.
Measures of central/total time 4 and 8 weeks demonstrated
that loss of anxiety readily occurred in uninfected mice but
not HIV-1 infected animals. These animals showed contin-
ued anxiety by thigmotaxis [30]. These tests best assess ex-
ploratory behavior, locomotor activity and anxiety-like
behavior and were employed based on the fragile nature of
the animals that would not tolerate the more rigorous
Morris water maze testing.
Multispectral fluorescence imaging of immunohistology
Neuronal and glial antigens were analyzed by multispec-
tral fluorescence imaging of replicate brain regions at
study termination. Images of each fluorescent spectral
component were analyzed following staining. Neuronal
density was assessed using neuronal microtubule associ-
ated protein-2 (MAP2) and neurofilament (NF). Synaptic
density was assessed using synaptophysin (SYN). Activa-
tion of astrocytes was assessed using glial fibrillary acidicFigure 4 Immunofluorescence staining of neuronal and glial antigens
were immunostained with MAP2, SYN, NF, GFAP, MAG and Iba1 antibodies
whisker barrel (WB), corpus collosum (CC) and Dentate gyrus, (DG) are show
(B) Density of antigen expression quantified in different brain regions are s
imaging. Decreased expression of MAG and NF in WB, CC and DG regions
increase in reactive microglia and astroglyosis (GFAP) was observed in DG.
WB and CC. Genu of corpus callosum from infected animals show decrease
mean ± SEM and *denotes p < 0.05.protein (GFAP). Microglial activation was measured
using ionized calcium binding adaptor molecule 1 (Iba-1).
Oligodendrocyte numbers and integrity were measured
by myelin associated glycoprotein (MAG) and myelin
oligodendrocyte glycoprotein (MOG) antigens. (Figure 4).
These antigens are expressed as fluorescence intensity per
μm2 (Figure 4B). Data from 20 infected animals were com-
pared to 10 uninfected controls.
SYN expression showed punctate and diffuse distribu-
tion in cortical areas of control animals, but in case of
HIV-1 infected animals, SYN labeled regions were ir-
regularly shaped with significantly decreased expression
and fluorescence intensity in the M2 region of the cortex
(Additional file 2) with a trend towards decreased SYN
in the whisker barrels (Figure 4B). No significant altered
expressions of SYN were seen in the 4 subregions of
hippocampus. GFAP expression was increased in 3 re-
gions of hippocampus (CA1, CA3 (Additional file 2) and
DG (Figure 4)). This reflects astrocyte activation re-
sponses that commonly follow HIV-1 infection. Micro-
glial expression, measured by Iba-1 staining, increased in
the M2 region of the cortex (Additional file 2), the whis-
ker barrels, and the dentate gyrus (Figure 4). In contrast,following HIV-1 infection. Paraffin embedded 5 μM brain sections
. (A) Representative images captured at 40× magnification from
n for those markers significantly deregulated after HIV-1 infection.
hown for both HIV-infected and uninfected mice by multispectral
of infected animals compared to uninfected controls. Significant
Oligodendrocyte associated myelin (MOG) was reduced both in
d expression of MAG, MOG and NF in infected mice. Values are
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served in the whisker barrels and corpus callosum of
HIV-1 infected mice (Figure 4) while changes in NF ex-
pression between infected and uninfected brains were
not seen in the hippocampus (Additional file 2). These
results, taken together, demonstrate that HIV-1 infected
humanized mice are distinct from previous injection
models of HIV-1 encephalitis where glial inflammatory re-
sponses drive more significant neurodegeneration [5,23].
Nonetheless, the reduced presynaptic and neurofilament
expression seen in the cortical and white matter regions of
the humanized virus-infected mice indicate ongoing neu-
rodegeneration potentially compatible with an orthograde
axonopathy.
We next analyzed MOG and MAG in the white and
grey matter regions to assess oligodendrocyte and mye-
lin density. MOG, is a myelin component of the CNS
and responsible for maintenance of the myelin sheath,
cell adhesion and oligodendrocyte microtubule stability.
MOG is localized on the oligodendrocyte cell surface
and on the outermost lamellae of mature myelin. MAG
is a nervous system cell surface adhesion protein that is
involved in linking myelinated cells to neuronal axons.
Like myelin, MAG inhibits axonal outgrowth and con-
tributes to the inhibitory properties of myelin. We ob-
served significantly decreased MAG expression in the
whisker barrels, corpus callosum, and hippocampus re-
gions DG (Figure 4), CA1, and CA3 (Additional file 2)
in HIV infected animals. Decreased MOG expression
was observed in the whisker barrels and corpus callosum
of infected animals (Figure 4) suggesting loss of axonal
fiber elements responsible for HIV-1 associated grey and
white matter damage.
Correlations between antigens and viral load (VL)
Mean results provide a picture of damage focused in the
cortex and white matter tracts. Hippocampus is affected
primarily with inflammation. The degree of damage is as-
sociated, in measure, with the mean virus concentration in
the blood over the course of infection. We hypothesized
that variability between individual mice infection level (VL
range 5 × 104 to 6 × 106 copies/ml blood) would lead to
differing severities of neuronal disease as reflected by
quantitative histological measures. Surprisingly, there were
no significant correlations between the virus levels and the
quantitative immunohistology. Only trends between MAG
reductions in the corpus callosum (r = -0.386, p = 0.1) and
GFAP in the dentate gyrus (r = -0.399, p = 0.098) were
found.
Neuroimaging
Within a subset of the animals studied we acquired 1H
MRS and DTI at four week intervals from preinfection, to
16 weeks post infection in both infected animals (n = 8)and uninfected humanized NSG mice as controls (n = 7).
In addition to comparing the groups over time to deter-
mine the kinetics of brain pathology in this model, results
for the individual infected animals were tested for correla-
tions to virus levels and histopathology to aid in the inter-
pretation of changes observed.
1H MRS
Mean metabolic consequences of HIV-1 infection as com-
pared to uninfected animals can be seen in the cerebral
cortex (Figure 5A, B). Reduced NAA and increased GABA
were seen at 12 weeks and reversed at 16 weeks in the
cerebral cortex but not in the cerebellum (Figure 5C, D).
Notably, a large increase in lactate was observed in the
cerebral cortex at 16 weeks after infection (Figure 5A, B).
Other metabolic effects of infection include reductions of
creatine and choline in the infected cerebral cortex over
time (Additional file 3) which is not seen in the cerebel-
lum (Additional file 4). These changes are subtle and not
significantly different from what is generally observed in
uninfected animals. Indeed, in the cerebral cortex of in-
fected animals the reductions of choline and creatine were
significantly different only from the preinfection levels of
the same animals.
Correlations between cortical metabolites and VL
To further examine the relationship between blood virus
levels and brain pathology, we investigated the correla-
tions between end-stage (16 week post infection) metab-
olite concentrations and the mean blood virus level over
the course of infection. Only one of the metabolites had
a significant correlation with mean virus concentration,
lactate (r = 0.857, p = 0.024) with a trend towards correl-
ation with myoinostitol (r = -0.714, p = 0.088). While in-
creasing lactate would be expected with higher viral
loads, decreasing myoinostitol with higher viral loads is
unexpected, as increased neuroinflammation is pre-
sumed to be associated with increased myoinostitol. In
order to further explore these effects, we investigated
the correlations between 16 week post infection metab-
olite concentrations and quantitative immunohistology
in the cerebral cortex.
1H MRS cortical metabolites and neuronal,
oligodendrocyte and glial markers
The correlations between metabolite concentrations at
the end-point of the study with cortical markers for synap-
tic density (SYN), glial activation (Iba-1, GFAP), and
oligodendrocyte-associated proteins density (MAG, MOG)
were measured between the cortex spectrum and the
quantitative histology from the M2 region of the cortex.
Significant correlations were found between reduced
MAG in the M2 region of the cerebral cortex (M2c) and
reduced 16 week concentrations of the metabolites
Figure 5 Metabolite levels (Means ± SEM) expressed as a percentage of total signal acquired over time from 1H MRS scans of (red)
HIV-1 infected (n = 8) and (black) uninfected humanized mouse controls (n = 7). (A) Region selected for spectral acquisition from the
cerebral cortex. (B) Selected metabolite levels are measured from the cerebral cortex. Time zero, in infected mice is before infection with
subsequent spectra acquired every four weeks to 16 weeks in both infected and control mice. (C) Region selected for acquisition of spectrum
from cerebellum. (D) The same metabolites as shown in (B). Time courses of all metabolites are shown in Additional files 3 and 4. *p < 0.05
control versus HIV-1 infected mice, +p < 0.05 vs time zero in control mice, (red “+” symbol) p < 0.05 versus preinfection in infected mice.
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http://www.molecularneurodegeneration.com/content/9/1/58glutamate (r = 0.929, p = 0.024), myoinostitol (r = 0.857,
p = 0.024) as well as a trend for increased taurine (r =
-0.750, p = 0.066) (Figure 6I-K). In addition, there was a
trend for increased NAA (r = -0.714, p = 0.088) and creatine
(r = -0.750, p = 0.066) to correlate with reduced M2c MAG
(Figure 6A, E, I-L). Similar, but opposite relationships
existed between SYN and NAA (r = 0.893, p = 0.012), and
creatine (r = 0.857, p = 0.024) (Figure 6B, F). In addition,
there was a tendency for increased GFAP levels to correlate
with reduced NAA (r = -0.714, p = 0.088) (Figure 6D). Fi-
nally, it was also found that levels of lactic acid showed a
trend towards correlating with MOG (r = 0.750, p = 0.066)
(Figure 6H). This provides an overall picture of cortical me-
tabolism changes from HIV-1 infection showing that pro-
cesses leading to synaptic loss are associated with loss ofFigure 6 Correlations between cortical metabolites at 16 weeks after
measured in the M2 region of the cerebral cortex. (A-D) NAA versus MAG,
MAG, SYN, and MAP2 are illustrated. (H) Lactate versus MOG. (I-L) MAG ver
respectively were analyzed in these data sets.NAA and creatine, neuroinflammation being associated
with NAA loss, while reduced MAG are associated with
increases in NAA, creatine, taurine, and reductions in
glutamate and myoinostitol. Certainly, these associations
cannot be over interpreted, but are generally in agreement
with expected metabolic effects of inflammation, synaptic
loss, and loss of oligodendrocytes-associated proteins in the
cortex of these infected animals.
DTI
DTI metrics investigated include FA, Dav, longitudinal dif-
fusivity (λl) and transverse diffusivity (λt) (see Materials
and Methods) in brain regions. These were measured in
the hippocampus [CA1, CA2, CA3 and dentate gyrus
(DG)], in cortex (whisker barrels, middle cerebral cortex,infection and quantitative multispectral histology. The latter was
SYN, MAP2 and GFAP respectively are shown. (E-G) Creatine versus
sus myoinostitol, taurine, glutamate, and glutamate and glutamine,
Figure 7 (See legend on next page.)
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(See figure on previous page.)
Figure 7 DTI metrics. (A) Brain regions analyzed for DTI metrics. (B) Fractional anisotropy (mean ± SEM) in (top) CA1, CA3, and dentate gyrus
(from left to right) and (bottom) frontal cortex, middle cerebral cortex, and splenium of the corpus callosum (from left to right) as shown in
(A). (red “*” symbol) p < 0.05 control (n = 7) vs infected (n = 8) mice, +p < 0.05 versus time zero in control mice, (red “+” symbol) p < 0.05 versus
pre-infection in HIV-1 infected animals.
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(splenium and genu of the corpus callosum) (Figure 7A).
Metrics of uninfected control and HIV-1 infected animals
were compared over time. Results of individual mice and
brain regions were evaluated independently with correc-
tion for multiple comparisons. The most consistent and
notable changes were seen as reduced FA in hippocampus
and cortical regions relative to the uninfected controls
(Figure 7B). Many of these differences are accompanied by
increase in FA in the uninfected humanized mice that did
not manifest in the infected mice. It is also notable that
the cause(s) of such a reduction in FA in some regions are
reversible, including the dentate gyrus and splenium of
the corpus callosum, possibly indicating transient in-
flammatory processes occurring in these regions during
the course of infection. Other notable alterations included
increased diffusivity in white matter (Additional files 5, 6
and 7).
DTI and VL
End-point values of DTI metrics were tested for correl-
ation with mean viral loads in the individual infected
mice (Figure 8). Correlations with virus level were weak
and found only in cortical regions (M2 region of the cor-
tex and whisker barrels) in multiple DTI measures, but
only a trend of a single correspondence in DG and no
other regions. This suggests that the cortical regions are
the primary site of neuronal damage due to multifactor-
ial HIV-1 induced injuries. Exactly which factors are pri-
mary causes of this damage will be a matter for further
exploration. Nevertheless, further details regarding spe-
cific histological abnormalities and DTI metrics were
then explored in the cortical regions, hippocampus, and
corpus callosum.
DTI and neuronal, oligodendrocyte and glial markers
End-point values of DTI metrics were correlated with
quantitative histopathology in the individual infected
mice (Figure 9). Correlations were considered between
the DTI metrics within spatial subregions used for histo-
logical analysis which included cortical regions (M2Figure 8 Correlations between cortical DTI metrics and mean plasmaregion of the cortex (M2c), whisker barrel regions (WB)),
hippocampus regions (CA1, CA2, CA3 and the dentate
gyrus (DG)), genu of the corpus callosum, cerebellum, and
pons-medulla (brainstem) as delineated in Figure 7. The
most significant correlations were found in the cortical re-
gions, similar to virus level. It was observed that in the
whisker barrel region increasing mean diffusivity and de-
creasing FA correlate with increasing MAG and with in-
creasing Iba-1. In addition, FA reduced with NF loss. The
CA2 region of the hippocampus shows correlation of in-
creased diffusivity, especially the longitudinal diffusivity
with decreasing SYN with a similar trend with MAP2. No
significant correlations were found in the corpus callosum,
brainstem, or the cerebellum.
Discussion
There are expected similarities and noted differences be-
tween the neurological consequences of HIV-1 infection
in humans and in this mouse model. As for the former,
chronic infection in the mice leads to viral invasion of
the central nervous system and ingress of monocyte-
derived macrophages first into the meninges then the
perivascular spaces. Behavioral abnormalities follow but
more subtle in mice. They are coincident with CD4+ T
cell loss and high peripheral viral loads. Notably, mouse
infection leads to micro- and astro- gliosis and neuronal
loss that, like in humans, are region and animal specific.
Indeed, levels of infection and histopathological findings
in brain vary. Such variability rests in the extent of in-
flammation and neuronal damage. We have not yet ob-
served a true multinucleated giant cell encephalitis in
mice as is often present in humans and likely due to that
primary microglia and astrocytes are rodent-in-origin
and as such cannot be infected with the virus. Nonethe-
less, the finding in these rodents underlies the central
tenet of human disease in that few infected cells in the
brain can give rise to more wide spread alterations in
neural function underpinning the role of a virus-induced
metabolic encephalopthy. Importantly, it is the engage-
ment of the innate and adaptive immune system trig-
gered by the virus that are not only operative in theVL 16 weeks after HIV-1 infection.
Figure 9 Correlations between DTI metrics and histological quantifications in cortex and corpus callosum.
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man disease [5]. While this model replicates many of the
features of human disease, limitations exist. These include
the need for handling the animals in a P3 facility, the ex-
tensive work required for humanization, and the sterilizing
equipment and procedures necessary. In addition, as is
known the virus infects only human cells. Thus the feature
of infected microglia and astrocytes within the brain par-
enchyma are not replicated. Only peripheral monocytes
and macrophages and CD4+ T lymphocytes migrating
across the blood-brain barrier are infected and that infec-
tion is limited to the meninges and perivascular spaces
[5,21]. The relatively few infected cells are a likely source
for paracrine inflammatory responses that affect more
wide spread neural injuries. This serves, in part, to explain
the disconnection between absolute virus levels and
neuropathology. Additional advantages of this humanized
mouse model over more widely used transgenic mice that
express viral proteins or injection of HIV-1 infected cells
into brain areas affected by disease is that the current
model can accurately reflect ongoing viral infections ra-
ther that specific virotoxins or acutely generated cellular
inflammatory factors [5,31]. The model is thus a signifi-
cant step forward in studies of HIV-1 neuropathogenesis
as relevant neuroAIDS models were previously only avail-
able in nonhuman primates [32,33]. These were costly anddue to differences in viral dynamics did not always mimic
natural progression of CNS dysfunction. Thus, we devel-
oped this model as one possible solution. The new model
is based on the fact that immunodeficient mice trans-
planted with human hematopoietic CD34+ stem cells
(HSC) (hu-NSG) at birth enable long-term engraftment of
a functional human immune system and support chronic
HIV-1 infection [21,22,34]. Whether this could lead to
CNS consequences of persistent infections and the types
of behavioral, histologic and imaging abnormalities com-
mon in infected humans was not known. Our findings re-
solve such an unknown, in part, by demonstrating that
systemic HIV-1 infection leads to CNS damage and pro-
viding opportunities to detail brain metabolic dysfunctions
[35]. Interestingly, relationships between levels of viral
replication and virus-associated pathology did not uni-
formly occur. As ART is not always able to penetrate the
blood-brain barrier permitting reservoirs for viral muta-
tion; HIV infection of glia (astrocytes, microglia and blood
borne macrophages) persists in humans [36-38].
We had originally thought that viral load would be the
major determinant of neuronal dysfunction in the CD34-
NSG mice. This proved wrong. It is the lack of correlation
between virus levels and neurodegeneraation that demon-
strates that, as in humans, the mechanisms of neuronal
damage are complex and not simply a matter of absolute
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neuronal damage is not possible using the present results,
we find that the time course of chronic peripheral infec-
tion in the mice from the neuroimaging results indicates
initial inflammation, followed by neurodegeneration and
subsequent oligodendrocyte degeneration. Factors influen-
cing this progression likely include the pathobiologic de-
tails of infected immune cells and the effects of cytokine
and chemokine release on neuronal function. The ability
to explore these factors will be the subject of future studies
and likely will result in the ability to identify specific mech-
anisms involved in HIV-1 neurocognitive dysfunction.
Developing a database of co-registered histology, DTI,
and metabolic changes along with clinical indications in-
cluding CD4/CD8 and virus levels, and in the future,
protein, chemokine, cytokine and metabolomics, will aid
in our abilities to develop non-invasive monitors of dis-
ease status and understand the mechanisms of brain re-
action to peripheral infection even with relatively few
infected cells in brain.
Histological analyses demonstrated links between per-
ipheral viral infection and cortical neuroinflammation,
synaptic and neuronal loss, and damaged oligodendro-
cytes. This was seen especially in the whisker barrels.
Not surprisingly, NAA was reduced during chronic in-
fection with neuronal damage and neuroinflammation.
Also, increased NAA correlates with oligodendrocytes
dysfunction at the endpoint of the 16 week time course
of infection. Oligodendrocytes break down NAA to acet-
ate and aspartate via the aspartoacylase enzyme. In a re-
cent report oligodendrocytes have been shown to play
an important role along with neurons and astrocytes to
form a tri-cellular compartment [39]. Glial and neuronal
cells communicate by interchange of NAA, with neur-
onal NAA formation in synaptosomal mitochndria [40],
oligodendrocytes breakdown of NAA to provide acetyl
groups for myelin synthesis [41], and release aspartate
and acetate to be taken up by neurons for resynthesis of
NAA. The time course of NAA in infected animals sug-
gests that inflammation and neuronal damage start early
in infection, with oligodendrocyte dysfunction and loss
occurring later in the time course of infection in this
animal model. It was also found that creatine shows a
similar correlation as neuronal damage correlates with
decreased creatine and oligodendrocytes dysfunction
correlates with a creatine increase. Dysfunction of oligo-
dendrocytes have been seen in human HIV-1 infection
as global reduction in myelination, reflected by reduced
MRI magnetization transfer [42]. Creatine increase has
been shown in the white matter during acute stages of
accelerated simian immunodeficiency virus infection
[43] and similarly increased in the frontal white matter
of antiretroviral naïve HIV+ humans while decreasing in
deep gray matter (basal ganglia) in relation to dementiaseverity [44]. Creatine reduction has been shown in some
neurodegenerative disorders using either internal water sig-
nal or total metabolite concentrations as a normalization
factor. Creatine reduction has been demonstrated in mild
cognitive impairment [45] and in the prefrontal cortex of
adults with autism spectrum disorders [46].
Correlations between DTI and histology provide clues
to viral neuropathogenic mechanisms. Increased diffusivity
and decreased fractional anisotropy were associated with
both neuroinflammation and neuronal damage. Neuronal
damage is mostly associated with increased transverse dif-
fusivity, as opposed to gliosis which correlated with mean
diffusivity. Conversely, loss of oligodendrocyte function is
associated with decreased diffusivity and increased frac-
tional anisotropy. These findings are clearly linked to
MAG distribution and staining intensities in the infected
animals. MAG may serve as a receptor for neuronal ligand
(s) that modulate glial responses. The increase in activated
microglia in the somatosensory cortex and white matter
may be responsible for the NF and presynaptic reductions
seen mediated through neurotoxic factors.
The gold standard in the diagnosis of HAND is neuro-
psychological abnormalities [47,48]. We demonstrated
impaired ability to recognize and habituate to a new en-
vironment following HIV-1 infection. Cognitive deficits
were also seen in mice injected intracranially with HIV-1
infected human macrophages and transgenic animals ex-
pressing HIV-1 proteins [49-54]. These abnormalities
were more significant than what was seen in the current
model likely due to the concentration of virotoxins and
the resultant high degree of inflammation [49,55]. NF
loss in cortical regions and increase in astrocyte activa-
tion in hippocampus as well as altered metabolites in
these regions may also contribute to the behavioral ab-
normalities and memory loss. Moreover, the behavioral
changes observed in our mice (anxiety and memory loss)
parallel some of the dysfunctions reported by the National
Institute on Mental Health cohort followed by the CNS
HIVAnti-Retroviral Therapy Effects Research (CHARTER)
group. These studies used standardized neuropsychological
tests. ART-associated improvements in verbal fluency, in-
formation processing speeds, and motor domain function
were noted [56]. Interestingly, patients continued to show
mild deficits in learning and memory and executive func-
tions despite ART [3,57]. Whether changes in the cortical
impairment link to specific pathobiological outcomes
remain of considerable interest [3]. Changes in synaptic
plasticity by neuroinflammation resulted in subtle memory
losses with habituation and demonstration of anxiety with
HIV-1 infection attributing to decreased hippocampal
integrity [58]. Interestingly, reduction in creatine levels
following creatine kinase knock out led to reduced hippo-
campal fiber formation and deficit in open field habituation
[59]. Evidence of such behavioral abnormalities in this
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in mirroring some aspects of the human disease.
Persistent systemic viral replication affects memory
and lead to anxiety, neuroinflammation and defects in
neural metabolism [60-64]. The notable features of HIV
neuropathogenesis include infection of the nervous sys-
tem by invading leukocytes that traverse the blood-
brain-barrier with blood borne perivascular macrophages
and microglia infection. Glial activation, white matter
pallor, neuronal injury and subsequent neuronal death
occur through exposure to viral proteins and cellular
neurotoxic factors [65]. These are also seen in HIV in-
fected immune deficient mice [23]. Neuronal injuries
may be sped by active viral replication in peripheral
lymphoid tissues [66].
Conclusions
In conclusion, we provide evidence that this murine model
of viral infection produces neurocognitive dysfunction as a
consequence of systemic HIV-1 infection. This model will
be useful for investigating mechanisms of HIV-1 neuro-
pathogenesis. The combination of behavioral tests, ad-
vanced neuroimaging, and histology are a powerful
combination that is best used to detail some of the neuro-
pathological processes caused by HIV-1 infection.
Methods
HIV infection of humanized mice
NOD/scid-IL-2Rgc
null (NSG) mice obtained from Jackson
Laboratories established breeding colonies (stock number
005557) and housed under pathogen-free conditions; done
in approval and in accordance with ethical guidelines for
care of laboratory animals as set forth by National Insti-
tute of Health and the University of Nebraska Medical
Center (UNMC IACUC 06-071-02FC). Human CD34+
hematopoietic stem cells (HSC) were obtained from fetal
liver (University of Washington, Laboratory of Develop-
mental Biology, supported by NIH award 5R24HD000836)
by magnetic bead selection (Miltenyi Biotech Inc., Au-
burn, CA), and NSG mice were humanized as described
previously [20]. Human immune system engraftment was
determined by flow cytometry in rodent peripheral blood
using antibodies to human pan-CD45, CD3, CD4, CD8,
CD14 and CD19 in a six-color combination (BD Pharmin-
gen, San Diego, CA). The percentages of CD4+ and CD8+
T-lymphocytes were obtained from the gate set on human
CD3+ cells. Humanized CD34-NSG mice were infected in-
traperitoneally with HIV-1ADA, a CCR5 utilizing virus at a
dosage of 104 tissue culture infective dose 50 (TCID50)/
mouse at 22 weeks of age. The levels of viral replication
were monitored and analyzed from plasma at defined time
points by an automated COBAS Amplicor System V1.5
(Roche Molecular Diagnostics) and expressed as copies of
viral RNA per ml sample (Viral load, VL) as previouslydescribed [22]. HIV-1ADA used for infection was propa-
gated in monocyte-derived macrophages [67].Real-time RT PCR
Total RNA from cortex was extracted using TRIzol
(Invitrogen, Carlsbad, CA) method. Recovered RNAs were
reverse transcribed to cDNA with random hexamers
(Invitrogen). Real-time quantitative PCR was performed
using an ABI PRISM 7000 sequence detector (Applied
Biosystems, Foster City, CA). Human CD45, and mouse
GAPDH expressions were analyzed using TaqMan gene
expression assays. For HIV-1 gag the primers and probe
used were: forward, 5′-ACATCAAGCAGCCATGCAA
AT-3′; and reverse, 5′-ATCTGGCCTGGTGCAATAGG-
3′ and probe (FAM), 5′-CATCAATGAGGAAGCT GC
AGAATGGGATAGA-3′ (TAMRA). Viral copies were cal-
culated from the standard curve using DNA from the 8E5
cell line (NIH AIDS reference reagent program).Behavioral testing
Behavioral testing was performed in a dedicated series of
animals that were not subjected to monthly neuroimag-
ing evaluations. Humanized mice were subjected to an
open field activity (OFA) testing after HIV-1 infection.
Control mice (n = 9) were left uninfected but tested at
the same age as infected mice (n = 7). OFA testing was
conducted using a TruScan automated photo beam-
tracking arena (Coulbourn Instruments, Lehigh Valley,
PA). The arena is equipped with two photo beams, the
first one measures the beam breaks in x and y axes
closer to the floor and the second measures movements
in z-plane. The number of horizontal and vertical beam
breaks assessed horizontal and vertical activity, respect-
ively. Animals were acclimated to the experimental room
for at least 1 hour prior to testing. Mice were individu-
ally placed in the center of a 25.4 × 25.4 cm square
arena and left to freely explore for 20 minutes. Parame-
ters were automatically monitored and measured by
TruScan 2.02 software, which included total distance
travelled (ambulatory), velocity, ambulatory time, rearing
and vertical movements. OFA testing was performed
over three consecutive days in the same arena to meas-
ure habituation to the new environment. All trials were
conducted at the same time of the day (from 13:00 to
18:00 hours). The arena was cleaned before testing each
animal using 70% ethanol to remove any olfactory cues
of human or mouse origin. For longitudinal OFA using a
new set of mice, testing was done at pre-infection and 4
and 8 weeks post infection. At each time point, trials
were performed on three consecutive days. The arena
was divided into darker marginal zone, which is a 2.5-
beam margin of the walls and brighter central zone. Time
spent and distance travelled in the center compared to
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iety behavior.
Neuroimaging
All neuroimaging studies were performed using a 7 Tesla/
16 cm Bruker Pharmascan or a 7 Tesla 21 cm Bruker
Biospec (Karlsure, Germany) MRI/MRS system. Prior to all
scans, mice were anesthetized by inhalation of 1-2% isoflur-
ane in a nitrous oxide/oxygen mixture. The animals were
subsequently placed into a custom animal holder equipped
with a receive only surface coil. Data were acquired using
volume transmit and surface coil receive. Respiratory moni-
toring, gating of the MRI system, and temperature monitor-
ing were done using an SA instruments model 1025 MRI
compatible physiological monitoring system (Model 1025,
SA Instruments, Stony Brook, NY).
1H MRS acquisitions
Single voxel localized spectra were acquired in the cere-
bral cortex (Figure 4A) and cerebellum (Figure 4C) using
point resolved spectroscopy (PRESS) with outer volume
suppression and high bandwidth pulses to optimize se-
quence performance. Spectra were acquired with a repeti-
tion time of 4 seconds, echo time of 50 ms, 320 averages.
Spectroscopic analyses
Spectroscopic data were processed by removal of residual
water signal using the HLVSD filter. Spectra from 1H
MRS data sets were curve fit in the time domain using the
QUEST algorithm [68,69] in jMRUI version 4.0 (http://
www.mrui.uab.es/mrui), which fits results to a sum of in-
dividual metabolite spectra (basis set, Figure 10A) to de-
termine metabolite concentrations (Figure 10B) [22].
Results were expressed as a percentage of the sum of all
14 metabolites (alanine, aspartic acid, creatine, gamma-
aminobutyric acid, glutamine, glucose, glutamate, glycine,Figure 10 1H MR spectrum and fit. A: Basis set showing the spectra used
PRESS spectrum. B: In vivo spectrum, fit individual components, and the di
single acquisition located in the cerebral cortex.glycerophosphocholine, lactic acid, myoinostitiol, NAA,
phosphocholine and taurine) as a semi-quantitative method
for reporting metabolite concentrations in institutional
units (I.U.). Glycerophosphocholine and phosphocholine
were added and reported as total choline containing
compounds.DTI
DTI data were obtained using an actively decoupled
72 mm volume coil transmitter and a laboratory built
1.25 × 1.5 cm surface coil receiver. Reference coronal
mouse brain images were obtained using 3D FLASH with
acquisition parameters of 24 × 24 × 16 mm field-of-view
(FOV), a 128 × 128 × 32 matrix, 35° flip angle, 50 ms repe-
tition time (TR), 3 ms echo time (TE), and two averages
for a total acquisition time of 7.5 min. DTI data were ac-
quired using single-shot diffusion-weighted spin-echo
echo-planar imaging (TE = 43 ms). Respiratory gating was
used to prevent motion artifacts. Acquisition was repeated
at TR = 10–15 s depending on respiratory rate and one
shot per breath. EPI acquisition parameters included: 14
slices, 200 kHz bandwidth, 96 × 96 in-plane acquisition
zero-filled to 256 × 256, and a 0.5-mm slice thickness. The
diffusion encoding used was a balanced, rotationally in-
variant and alternating polarity icosahedral scheme (12 di-
rections) as detailed in our previous work [70].
Analyses of the diffusion-weighted data were performed
using custom programs written in IDL as previously
described [71-73]. Analyses produced maps of the tensor
diffusivities (λ1, λ2, λ3), mean diffusivity (Dav) where: Dav =





λ1−λ2ð Þ2þ λ2−λ3ð Þ2þ λ1−λ3ð Þ2
λ21þλ22þλ23
r
. Transverse (λ⊥ = (λ2 +
λ3)/2) and longitudinal (λ|| = λ1) components of the diffu-
sion tensor were obtained as previously described [74].to deconvolute the individual components in the in-vivo localized
fference between the fit and the original spectrum (residual) from a
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For immunocytochemical analyses mouse tissues were
post-fixed for 24 hours in 4% paraformaldehyde (PFA)
and embedded in paraffin. Brain sections were selected
from the corresponding regions analyzed by DTI. Five
micron paraffin embedded brain sections were stained
with mouse monoclonal antibodies to 200 and 68 kDa
neurofilaments (NF) (clone 2 F11; 1:200; Dako), synapto-
physin (SYN) (clone SY38; 1:1000; EMD Millipore,
Temecula, CA), myelin oligodendrocyte glycoprotein
[(MOG (D-10): sc-166172; 1:500; Santacruz Biotech,
Inc.] and myelin associated glycoprotein [MAG (G-11):
sc-166780; 1:500; Santacruz Biotech]. Rabbit polyclonal
antibodies were applied to glial fibrillary acidic protein
(GFAP, 1:1000; Dako), microtubule-associated protein 2
(MAP2, 1:500; EMD Millipore) and ionized calcium
binding adaptor molecule 1 (Iba1; 1:500; Wako chemi-
cals). The signals were captured with secondary anti-
mouse and rabbit antibodies conjugated to fluorescent
probes Alexa Fluor 488 and Alexa Fluor 594 (1:200;
Invitrogen). Nuclei were labeled with 4′, 6-diaminido-2-
phenylindole (DAPI). Slides were then cover-slipped with
ProLong Gold anti-fade reagent mounting media (Invitrogen,
Carlsbad, CA). Images were captured at wavelengths
(20 nm intervals between 420 nm to 720 nm) encompass-
ing the emission spectra of the probes using separate
fluorescent filter blocks (DAPI, FITC HYQ, Texas Red
HYQ; Nikon Instruments, Inc.), with 20× and 40× objec-
tives. The fluorescence emission of each probe and auto-
fluorescence of the tissue samples were analyzed by the
multispectral imaging/image analysis using a Nuance EX
camera [22] fixed to a Nikon Eclipse E800 using Nuance
software (Cambridge Research and Instrumentation, Wo-
burn, MA). Two to four images per region were obtained
for each protein from two to four brain sections/mouse.
Results were averaged from each individual area for each
antigen to represent density and used as a single result per
mouse for statistical analysis. The design for statistical
analysis consisted of one between subject factor consid-
ered as a fixed effect and evaluated with a random effects
ANOVA model to account for the anticipated correlated
data due to multiple observations from each animal. Dif-
ferences between infected and uninfected brain staining
are illustrated in Figure 4B. The quantitation data were
expressed as average ± SEM of signal counts relative fluor-
escence units/ μm2.
Statistical analyses
Statistical analyses were performed in SAS 9.4 (SAS Insti-
tute, Inc, Cary, N.C.). The design consisted of one between
factor (infected/control) and one within factor (time, con-
sisting of 5 measurement collected over 4-week intervals).
The data were evaluated with a repeated measures
ANOVA model that applied an autoregressive covariancestructure to account for the correlated nature of the data.
Time and treatment were entered as fixed effects and their
main effects and interactions were evaluated. Average DTI
measures for the infected versus the uninfected control
group were compared at each of the five time points (0, 4,
8, 12, 16 weeks). Within each group, the measurements at
times 4, 8, 12, and 16 were compared to week 0. To ac-
count for multiple comparisons among the group means,
adjustments to the p-values and confidence intervals for
the differences were computed with simulation tech-
niques, the recommended method for adjustments due to
multiplicity for the repeated measures ANOVA model
[75]. The means with confidence intervals were then
depicted with graphs, which indicate whether a signifi-
cance difference exists between the two group means at
each time point (*) and the difference of the means for
week with the pre-infection time for each group (^).
Histological results provided with up to eight response
variables in each section. The design consists of one be-
tween subject factors (HIV infected compared to unin-
fected controls), treated as a fixed effect. Data existing in a
section for the response variables contained from 2 to 4
measurements collected from each subject. The data were
evaluated with a random effects ANOVA model to ac-
count for the correlation within each mouse. Correlations
were performed using Spearman correlations with exact
p-values to account for small numbers of samples. All stat-
istical significance tests were two-sided. All statistical ana-
lyses were generated with PROC MIXED and PROC
FREQ from SAS/STAT. Behavioral data obtained from
OFA were analyzed using SAS/STAT and statistical signifi-
cance was calculated using post-hoc t-test. Graphs were
produced with Microsoft Excel software. A p less than
0.05 was considered significant.Additional files
Additional file 1: Figure S1. Identification of HIV-1 infected human cells
in spleen and brain. A. Five micron thick paraffin-embedded tissue sections
were double florescent stained for human CD14 (macrophages) and
HIV-1p24 (viral core protein, top panels) or human CD4 (T lymphocytes) and
HIV-1p24 on the bottom panels. Merged pictures show HIV-1 infected
(pictured in yellow) human CD14 or CD4 positive cells, original magnification
400×. B. Sections of brain tissues were peroxidase-stained for HLA-DR (human
immunocytes) in meninges, brain parenchyma and perivascular spaces.
HIV-1p24 cells are pictured on corresponding adjacent sections. Top insets
show a magnified view of identified cells (see arrows). Top panel shows a
HIV-1p24 cell simultaneously stained for human CD163 (macrophages). C.
Sections showing perivascular human CD163 positive macrophages. B and C
are at original magnification 200× and insets at 1000×.
Additional file 2: Figure S2. Complete set of histology results
comparing uninfected humanized mice (green, n = 10) to HIV-1 infected
controls (red, n = 20) from A: M2 region of the cerebral cortex, B: Whisker
barrel region of the cerebral cortex, C: Corpus callosum, D: CA1 region of
the hippocampus, E: CA2 region of the hippocampus, F: CA3 region of
the hippocampus, G: Dentate gyrus, H: Cerebellum and I: Brainstem.
*Significant differences (p < 0.05).
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SEM) expressed as a percentage of total signal contribution from 1H MRS
scans of (red) HIV-1 infected humanized mice (n = 7) and (black) uninfected
humanized mice (n = 7) over time. Time zero in infected mice is preinfection
with subsequent spectra acquired every four weeks up to 16 weeks in both
infected and uninfected mice. *p < 0.05 control vs infected mice, ^p < 0.05 vs
time zero in control mice, (red “^” symbol) p < 0.05 vs preinfection in infected
mice.
Additional file 4: Figure S4. Cerebellum Metabolite Levels (Means ±
SEM) expressed as a percentage of total signal contribution from 1H MRS
scans of (red) HIV-1 infected humanized mice (n = 7) and (black) uninfected
humanized mice (n = 7) over time. Time zero, in infected mice is preinfection
with subsequent spectra acquired every four weeks up to 16 weeks in both
infected and uninfected mice. *p < 0.05 control vs infected mice, ^p < 0.05
vs time zero in control mice, (red “^” symbol) p < 0.05 vs preinfection in
infected mice.
Additional file 5: Figure S5. Comparison of DTI metrics (mean ± SEM)
in CA1, CA2, CA3, and Dentate Gyrus (from left to right) as shown in
Figure 7 in uninfected (black, n = 7) and HIV-1 infected (red, n = 8)
humanized mice. Shown are (from top to bottom) Mean diffusivity (Dav),
Fractional anisotropy (FA), transverse component of diffusivity ((λt), and
longitudinal component of diffusivity ((λl). (red “*” symbol) p < 0.05
control vs infected mice, tp < 0.05 vs time zero in control mice,
(red “^” symbol) p < 0.05 vs preinfection in infected mice.
Additional file 6: Figure S6. Comparison of DTI metrics (mean ± SEM)
in frontal cortex, middle cerebral cortex, M2 region of cerebral cortex,
and whisker barrels (from left to right) as shown in Figure 7 in uninfected
(black, n = 7) and HIV-1 infected (red, n = 8) humanized mice. Shown are
(from top to bottom) Mean diffusivity (Dav), Fractional anisotropy (FA),
transverse component of diffusivity (λt), and longitudinal component of
diffusivity (λl). (red “*” symbol) p < 0.05 control vs infected mice, tp < 0.05
vs time zero in control mice, (red “t” symbol) p < 0.05 vs preinfection in
infected mice.
Additional file 7: Figure S7. Comparison of DTI metrics over time
(mean ± SEM) from left to right in the Genu of the Corpus Callosum (CC)
and the Splenium of the CC, as shown in Figure 7. Results are shown
from uninfected (black, n = 7) and HIV-1 infected (red, n = 8) humanized
mice. Shown are (from top to bottom) Mean diffusivity (Dav), Fractional
anisotropy (FA), transverse component of diffusivity (λt), and longitudinal
component of diffusivity ((λl). (red “*” symbol) p < 0.05 control vs infected
mice, tp < 0.05 vs time zero in control mice, (red “t” symbol) p < 0.05 vs
preinfection in infected mice.
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